Background:: A total of 254 senior consultant gastroenterologists with valid e‐mail addresses were identified from the membership list of the British Society of Gastroenterology (BSG) 2007.
Methods:: They were sent by e‐mail a questionnaire which dealt with aspects of clinical practice and addressed cancer prevention in ulcerative colitis (UC). Replies were received from 97 clinicians (38% response rate).
Results:: Ninety‐one (94%) advised patients with established UC to take 5‐aminosalicylate (5‐ASA) compounds for life. Seventy‐two of the 91 (79%) clinicians co‐prescribed 5‐ASA compounds with immune modulators for patients with UC. Only 3 clinicians advised patients to take folic acid as a daily supplement. A median of 20% (interquartile range 10%–50%) of their patients with UC were co‐prescribed a 5‐ASA compound and azathioprine or 6‐mercaptopurine. Of these, a median of 3.5% (interquartile 1%–5%) developed neutropenia.
Conclustions:: Future research needs to be directed at the long‐term maintenance treatment and to address questions about which drugs should be used, in what combinations, and with what frequencies.